Ask AI
ProCE Banner Activity

Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress

Slideset

Download this slideset from our live meeting series to learn more about the optimal use of immune-oncology−based therapy for patients with RCC.

Released: June 26, 2020

Review Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by a medical education grant from Exelixis, Inc.

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from

Eisai

Pfizer, Inc.

Faculty Disclosure

Primary Author

Robert Motzer, MD

Jack and Dorothy Byrne Chair in Clinical Oncology
Kidney Cancer Section Head, Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Robert Motzer, MD: consultant: Merck; researcher (paid to institution): Bristol Myers Squibb, Eisai, Exelixis, Merck.